Our study suggests that the association between pretreatment levels of ETV4 and the efficacy of anti-PD-1/anti-CTLA-4 therapy may be explained by the positive regulation of PD-L1 expression by ETV4 in melanoma. The gene discussed is ETV4; the disease is melanoma.